QNRX

Quoin is a pre-revenue clinical-stage biotech: zero product sales in every year shown (FY2021–FY2025) and no revenue expected 'unless and until we successfully complete development and obtain marketing approval… which we expect will take a number of years and is subject to significant uncertainty.' Value here rests entirely on QRX003 for Netherton Syndrome, now entering 'pivotal registrational' testing under an open IND. That is a genuine orphan-drug opportunity, but with no approved asset and no cash generation, the equity is a binary option on trial data, not a business you can value on fundamentals or multiples — there is no P/E, P/S or ROE to anchor to (ROE is -120.5% purely because losses dwarf a thin equity base).

The balance sheet is the disqualifier. Cash & equivalents are just $3.82M against FY2025 operating cash burn of -$13.5M — on the order of a single quarter of runway. Management explicitly warns it 'will need to obtain further funding through public or private offerings… debt financing… or [warrant] exercise' and that it 'may be unable to raise additional funds… on favorable terms or at all,' adding that outstanding warrants may 'expire without being exercised.' Net loss widened 76% YoY to -$15.8M as R&D jumped 172% to $9.80M — spending is accelerating into an empty tank, so a near-term dilutive raise is close to a certainty.